Analysis updated Oct 24, 2026 — scores and signals refreshed daily.
InfuSystem Holdings, Inc. (INFU) stock research. Updated Oct 24, 2026. Q-Score 63/100 — Buy. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Buy (63.0) (grade B). 27 signals analyzed (23 differentiated alt-data).
StoQuant's analysis of InfuSystem Holdings, Inc. (INFU) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
INFU stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-27 | $9.51 | $9.26 | $9.35 |
| 2026-08-04 | $12.50 | $9.88 | $12.32 |
| 2026-08-12 | $12.35 | $12.02 | $12.24 |
| 2026-08-20 | $12.38 | $12.10 | $12.20 |
| 2026-08-28 | $12.11 | $11.95 | $12.04 |
| 2026-09-08 | $12.12 | $11.81 | $11.89 |
| 2026-09-16 | $12.63 | $12.24 | $12.45 |
| 2026-09-24 | $12.86 | $12.50 | $12.69 |
| 2026-10-02 | $13.20 | $12.91 | $13.16 |
| 2026-10-12 | $13.82 | $13.51 | $13.60 |
| 2026-10-20 | $14.28 | $13.77 | $14.23 |
How InfuSystem Holdings, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CNTX | Context Therapeutics Inc. | $205M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $206M | — |
| TENX | Tenax Therapeutics, Inc. | $206M | — |
| NBP | NovaBridge Biosciences | $203M | — |
| WHWK | Whitehawk Therapeutics Inc | $209M | — |
View all Health Care stocks by valuation and signals →
InfuSystem Holdings, Inc. (INFU) scores Buy (63.0), with no measured dimension below 47. Its highest are analyst consensus at 81, technicals at 80, competitive moat at 62, across 5 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 81 |
| technicals | 80 |
| competitive moat | 62 |
| earnings quality | 55 |
| valuation | 47 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on InfuSystem Holdings, Inc. (INFU): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/INFU"><img src="https://stoquant.com/badge/INFU.svg" alt="InfuSystem Holdings, Inc. (INFU) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.